Radioligand therapy involves the application of radioactive atoms to advanced cancers. It helps in delivering the radiation to the target cells in the body. This therapy aims at limiting the damage around the tissues. For over a decade, targeted radiation with radioisotopes has been used in the treatment of thyroid cancer.
 |
| Get the sample pages of this report: https://bit.ly/3K4WnXi |
Presently, radioligand therapy is widely utilized in the field of oncology. Several such therapies have received approval for a number of cancer treatments, including metastatic castration-resistant prostate cancer, and midgut neuroendocrine tumours. It is also known as targeted radiotherapy, systemic radiation therapy, targeted radionuclide therapy, and peptide-receptor radionuclide therapy.
The specialists in nuclear medicine will require fully integrated multidisciplinary cancer care teams, and precise resourcing to provide radioligand therapy in hospitals and nuclear waste facilities. These therapies have been effective in aiding the progression-free survival and quality of life for numerous patients.
The radioligand industry has garnered $7,785.6 million revenue in 2021, and it is projected to generate $13,073.9 million revenue in 2030, advancing at a rate of 5.9% in the coming future. The demand for radioligand therapy is rising with FDA-approved drugs showing low side effects.
Healthcare systems widely utilise and integrate radioligand therapy. It provides life-enhancing treatment for cancer patients with limited therapeutic options. It involves the integration of nuclear medicine to ensure it is precisely embedded into cancer care.
The major companies operating in the industry are; Novartis International AG, Telix Pharmaceuticals, Molecular Partners, Bayer AG, ITM Isotope Technologies Munice SE, Radio Medix, Pfizer Inc., and Janssen Global Services LLC.
Therefore, the rising prevalence of cancer propels the demand for radioligand therapy.
No comments:
Post a Comment